Picture of Hyperfine logo

HYPR Hyperfine News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Hyperfine Q4 revenue jumps, net loss narrows

Overview

US portable brain MRI maker's Q4 revenue rose 128% yr/yr, net loss narrowed

Full-year 2025 revenue grew 5.2%, gross margin improved to 50%

Outlook

Hyperfine expects 2026 revenue of $20 to $22 mln

Company expects 2026 cash burn of $26 to $28 mln, down 10% at midpoint

Result Drivers

SYSTEM SALES GROWTH - Q4 revenue increase driven by higher sales of Swoop systems, with 16 units sold versus 9 a year earlier

COST CONTROL - Lower research and development expenses helped narrow net loss

Company press release: ID:nBw3NCzqqa

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 EPS-$0.06
Q4 Net Income-$5.9 mln
Q4 Operating Income-$7.6 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy" Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 26.9% above its March 17 closing price of $1.30 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Hyperfine

See all news